Cartesian Therapeutics (RNAC) Asset Utilization Ratio (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q1 2026.

• Asset Utilization Ratio for Q1 2026 came in at 0.0, down 103.98% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0 (down 103.98% YoY), and the FY2025 annual result was 0.0, down 98.94% from the prior year.
• Asset Utilization Ratio retreated to 0.0 in Q1 2026 per RNAC's latest filing, from 0.0 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.76 in Q2 2022 and troughed at 0.0 in Q1 2026.
• A 5-year average of 0.27 and a median of 0.13 in 2023 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2022 and 2026: Asset Utilization Ratio soared 337.53% in 2022, then sank 103.98% in 2026.
• A 5-year view of Asset Utilization Ratio shows it stood at 0.64 in 2022, then slumped by 80.35% to 0.13 in 2023, then plunged by 32.35% to 0.09 in 2024, then slumped by 99.64% to 0.0 in 2025, then tumbled by 1131.95% to 0.0 in 2026.
• Business Quant data shows RNAC's Asset Utilization Ratio at 0.0 in Q1 2026, 0.0 in Q4 2025, and 0.0 in Q3 2025.